Announcements Trials

Browse Landscape

Phase

Phase 1 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 24 Neoplasm Metastasis 9 Neoplasms by Site 2 Neoplasms 2 Breast Diseases 2 von Hippel-Lindau Disease 1 Unilateral Breast Neoplasms 1 Skin Diseases 1 Sarcoma 1 Recurrence 1 Locally Advanced (Inoperable) or Metastatic Breast Cancer 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1 HR+/HER2- Breast Cancer 1 HER2+ Breast Cancer 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Carcinoma, Renal Cell 1 Breast Neoplasm Female 1 Breast Cancer Recurrent 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 5 Anastrozole 5 Letrozole 3 exemestane 2 Goserelin 2 ribociclib 1 palbociclib 1 entinostat 1 elacestrant 1 apatinib 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 RAD1901 1 Paclitaxel 1 Injections 1 Gonadotropin-Releasing Hormone 1 FCN-437c 1 Everolimus 1 Aromatase Inhibitors 1 AZD9833 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Breast Cancer × palbociclib × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡